Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease

World Journal of Hepatology

Volumn 6, Issue 4, 2014, Pages 160-168

  Castiella, Agustin ^a   Zapata, Eva ^a   Lucena, M Isabel ^b,c   Andrade, Raúl J ^b,c  

^a HOSPITAL DE MENDARO   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Autoimmune hepatitis; Drug induced autoimmune hepatitis; Drug induced autoimmune liver disease; Drug induced liver injury; Drugs

Indexed keywords

EID: 84901231423     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i4.160     Document Type: Editorial

References (83)

1. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-631 [PMID: 16496329 DOI: 10.1002/hep.21095]
2. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-774 [PMID: 12362579 DOI: 10.1016/S1089-3261(02)00025-9]
3. Seef LB. Drug-induced autoimmune hepatitis; drugs potentially implicated. AASLD-FDA-NIH-PhRMA-Hepatotoxicity special interest group meeting. 2007 presentations. Available from: URL: http: //www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/ucm076641.htm
4. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]
5. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176 [PMID: 18537184 DOI: 10.1002/hep.22322]
6. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006; 40: 757-761 [PMID: 16940892 DOI: 10.1097/00004836-200609000-00018]
7. Grasset L, Guy C, Ollagnier M. Cyclines and acne: pay attention to adverse drug reactions! A recent literature review. Rev Med Interne 2003; 24: 305-316 [PMID: 12763176 DOI: 10.1016/S0248-8663(02)00017-6]
8. Vierling JM. Autoimmune hepatitis and drugs. AASLDFDA- NIH-PhRMA-Hepatotoxicity special interest group meeting. 2007 presentations. Available from: URL: http: //www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ ucm076635.htm
9. Castiella A, Zapata E, Lucena E. Hepatotoxicity with autoimmune features. Analysis of the cases included in the Spanish Dili registry. Basic Clin Pharmacol Toxicol 2011; 109 (Suppl 3): 53 (abstract)
10. Heurgué A, Bernard-Chabert B, Diebold M, Vitry F, Louvet H, Geoffroy P. Drug-induced autoimmune hepatitis: a frequent disorder. Gut 2007; 56 (Suppl III): A271
11. Sugimoto K, Ito T, Yamamoto N, Shiraki K. Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology 2011; 54: 1892-1893 [PMID: 21725992 DOI: 10.1002/hep.24513]
12. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Druginduced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-2048 [PMID: 20512992 DOI: 10.1002/hep.23588]
13. Zapata E, Castiella A, Otazua P. Hepatitis autoinmune en Gipuzkoa, Pais Vasco: epidemiologia, indices diagnosticos e impacto de la edad en la histologia. Rev Esp Enferm Digest 2011; 103 (Suppl I): 137-138
14. Licata A, Butera G, Macaluso FS, Cabibi D, Craxi A, Almasio PL. Clinical features and outcomes of patients with druginduced autoimmune hepatitis. Dig Liver Dis 2012; 44 (Suppl 1): S12 [DOI: 10.1016/S1590-8658(12)60035-8]
15. Castiella A, Lucena MI, Zapata EM, Otazua P, Andrade RJ. Drug-induced autoimmune-like hepatitis: a diagnostic challenge. Dig Dis Sci 2011; 56: 2501-252; author reply 2501-2502 [PMID: 21674172 DOI: 10.1007/s10620-011-1787-7]
16. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-976 [PMID: 21327704 DOI: 10.1007/ s10620-011-1611-4]
17. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Björnsson E. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-939 [PMID: 21674554 DOI: 10.1002/ hep.24481]
18. Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011; 55: 747-749 [PMID: 21396413 DOI: 10.1016/j.jhep.2011.02.024]
19. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK. Susceptibility to amoxicillinclavulanate- induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347 [PMID: 21570397 DOI: 10.1053/j.gastro.2011.04.001]
20. Lucena MI, Kaplowitz N, Hallal H, Castiella A, García-Bengoechea M, Otazua P, Berenguer M, Fernandez MC, Planas R, Andrade RJ. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011; 55: 820-827 [PMID: 21338638 DOI: 10.1016/j.jhep.2010.12.041]
21. Egiguren L, Minondo L, Zapata E, Castiella A. [Patient with autoimmune hepatitis and idiopathic thrombocytopenic purpura after minocycline therapy]. Gastroenterol Hepatol 2007; 30: 565-566 [PMID: 17980139]
22. Heurgué-Berlot A, Bernard-Chabert B, Diebold MD, Thiéfin G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci 2011; 56: 2504-2505; author reply 2505 [PMID: 21698369 DOI: 10.1007/ s10620-011-1786-8]
23. Maíz B, Odriozola M, Blanco A, Fernández J, Castiella A. [Autoimmune hepatitis in a patient with uveitis]. Gastroenterol Hepatol 2005; 28: 656-657 [PMID: 16373020 DOI: 10.1016/S0210-5705(05)71534-X]
24. Romanelli RG, Almerigogna F. Uveitis as a presenting feature of autoimmune hepatitis. Am J Ophthalmol 2009; 148: 318-319; author reply 319-320 [PMID: 19619722 DOI: 10.1016/j.ajo.2009.05.002]
25. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521 [PMID: 16083708]
26. Ohmoto K, Yamamoto S. Drug-induced liver injury associated with antinuclear antibodies. Scand J Gastroenterol 2002; 37: 1345-1346 [PMID: 12465739 DOI: 10.1080/003655202761020687]
27. Hinrichsen H, Lüttges J, Klöppel G, Fölsch UR, Schmidt WE. Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol 2001; 36: 780-783 [PMID: 11444480 DOI: 10.1080/003655201300192076]
28. Bessone F, Hernandez N, Sanchez A. The Spanish-latin American DILI network: preliminary results from a collaborative strategic initiative. J Hepatol 2012; 58 (Suppl 1): S212-s213 [DOI: 10.1016/S0168-8278(13)60520-6]
29. Andrade RJ, Medina-Cáliz I, Stephens C. La hepatotoxicidad recurrente se asocia frecuentemente a manifestaciones de autoinmunidad. Gastroenterol Hepatol 2013; 36 (Espec Congre 1): 84
30. Ramachandran R, Kakar S. Histological patterns in druginduced liver disease. J Clin Pathol 2009; 62: 481-492 [PMID: 19474352 DOI: 10.1136/jcp2008.058248]
31. Heurgué A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, Louvet H, Frémond L, Geoffroy P, Schmit JL, Cadiot G, Thiéfin G. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol 2007; 31: 17-25 [PMID: 17273128 DOI: 10.1016/S0399-8320(07)89323-7]
32. Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep 2010; 4: 311 [PMID: 20863377 DOI: 10.1186/1752-1947-4-311]
33. Ju HY, Jang JY, Jeong SW, Woo SA, Kong MG, Jang HY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Jin SY, Kim HS, Kim BS. The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis. Clin Mol Hepatol 2012; 18: 213-218 [PMID: 22893872 DOI: 10.3350/cmh.2012.18.2.213]
34. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330 [PMID: 8229110 DOI: 10.1016/0895-4356(93)90101-6]
35. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-130 [PMID: 11124828 DOI: 10.1053/jhep.2001.20645]
36. Noël B. Autoimmune disease and other potential side-effects of statins. Lancet 2004; 363: 2000 [PMID: 15194268]
37. Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21: 17-24 [PMID: 17207162 DOI: 10.1111/j.1468-3083.2006.01838.x]
38. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29: 412-422 [PMID: 19826975 DOI: 10.1055/s-0029-1240010]
39. Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9: 188-193 [PMID: 19854301 DOI: 10.1016/j.autrev.2009.10.003]
40. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNFtargeted therapies. Best Pract Res Clin Rheumatol 2008; 22: 847-861 [PMID: 19028367 DOI: 10.1016/j.berh.2008.09.008]
41. Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008; 75: 737-739 [PMID: 18693125 DOI: 10.1016/j.jbspin.2007.12.009]
42. Toscano E, Cotta J, Robles M, Lucena MA, Andrade RJ. [Hepatotoxicity induced by new immunosuppressants]. Gastroenterol Hepatol 2010; 33: 54-65 [PMID: 19889479 DOI: 10.1016/j.gastrohep.2009.07.003]
43. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 2006; 1069: 322-345 [PMID: 16855160 DOI: 10.1196/annals.1351.031]
44. Goldberg AC, Bittencourt PL, Mougin B, Cançado EL, Porta G, Carrilho F, Kalil J. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 2001; 62: 165-169 [PMID: 11182227 DOI: 10.1016/S0198-8859(00)00234-2]
45. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816-822 [PMID: 8406354 DOI: 10.1002/hep.1840180411]
46. Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-323 [PMID: 9021941 DOI: 10.1002/hep.510250211]
47. Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, Ando A, Tsuji K, Inoko H. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103: 1041-1047 [PMID: 1354193]
48. Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badía I, Remondino G, Ciocca M, Ramonet M. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41: 146-150 [PMID: 7860360 DOI: 10.1016/0198-8859(94)90008-6]
49. Fainboim L, Pando M, Larriba J. HLA and autoimmune hepatitis. In: Charron EDK (ed). Proceedings of the 12th IHWC "Genetic diversity of HLA: Functional and Medival implications". Paris, 1997
50. Oliveira LC, Porta G, Marin ML, Bittencourt PL, Kalil J, Goldberg AC. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2011; 10: 189-193 [PMID: 20933106 DOI: 10.1016/j.autrev.2010.09.024]
51. Manns M, Scheucher S, Jentzsch M. Genetics in autoimune hepatitis type 2 (abstr). Hepatology 1991; 14: 60
52. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997; 92: 2197-2200 [PMID: 9399751]
53. Goldberg AC, Bittencourt PL, Oliveira LC, Ramasawmy R, Marin ML, Palacios SA, Kalil J, Porta G. Autoimmune hepatitis in Brazil: an overview. Scand J Immunol 2007; 66: 208-216 [PMID: 17635798 DOI: 10.1111/j.1365-3083.2007.01967.x]
54. Huppertz HI, Treichel U, Gassel AM, Jeschke R, Meyer zum Büschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995; 23: 204-208 [PMID: 7499793 DOI: 10.1016/0168-8278(95)80336-X]
55. Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989; 34: 1294-1297 [PMID: 2752878 DOI: 10.1007/BF01537282]
56. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995; 346: 608-609 [PMID: 7651006 DOI: 10.1016/ S0140-6736(95)91438-2]
57. Castellote J, Güell E, Porta F. [Autoimmune hepatitis following cytomegalovirus infection]. Med Clin (Barc) 2001; 117: 76 [PMID: 11446931 DOI: 10.1016/S0025-7753(01)72016-7]
58. Kaech C, Pache I, Raoult D, Greub G. Coxiella burnetii as a possible cause of autoimmune liver disease: a case report. J Med Case Rep 2009; 3: 8870 [PMID: 19830243 DOI: 10.4076/17 52-1947-3-8870]
59. Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011; 29: 4654-4656 [PMID: 21596082 DOI: 10.1016/j.vaccine.2011.05.002]
60. Perumalswami P, Peng L, Odin JA. Vaccination as a triggering event for autoimmune hepatitis. Semin Liver Dis 2009; 29: 331-334 [PMID: 19676005 DOI: 10.1055/s-0029-1233537]
61. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 Suppl 2: 12-21 [PMID: 9204405 DOI: 10.1016/S0168-8278(97)80492-8]
62. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-1832 [PMID: 3198757 DOI: 10.1172/JCI113798]
63. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfoamide hypersensitivity reactions by "in Vitro" rechallenge with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-289 [PMID:2913915 DOI: 10.7326/0003-4819-110-4-286]
64. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]
65. Chalasani N, Björnsson E. Risk factors for idiosyncratic druginduced liver injury. Gastroenterology 2010; 138: 2246-2259 [PMID: 20394749 DOI: 10.1053/j.gastro.2010.04.001]
66. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010; 5: 193-200 [PMID: 20107930 DOI: 10.1007/s11739-009-0342-4]
67. Etxagibel A, Julià MR, Brotons A, Company MM, Dolz C. Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J Med Case Rep 2008; 2: 25 [PMID: 18226219 DOI: 10.1186/1752-1947-2-25]
68. García-Cortés M, Borraz Y, Lucena MI, Peláez G, Salmerón J, Diago M, Martínez-Sierra MC, Navarro JM, Planas R, Soria MJ, Bruguera M, Andrade RJ. Liver injury induced by "natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev Esp Enferm Dig 2008; 100: 688-695 [PMID: 19159172]
69. Charier F, Chagneau-Derrode C, Levillain P, Guilhot F, Silvain C. [Glivec induced autoimmune hepatitis]. Gastroenterol Clin Biol 2009; 33: 982-984 [PMID: 19765927 DOI: 10.1016/ j.gcb.2009.07.034]
70. Primo J, Michavila J, Jiménez I. Efalizumab-induced autoimmune hepatitis. Gastroenterol Hepatol 2010; 33: 69-70 [PMID: 19800148 DOI: 10.1016/j.gastrohep.2009.07.005]
71. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44: e20-e22 [PMID: 19593165 DOI: 10.1097/ MCG.0b013e3181a745e7]
72. Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. J Med Case Rep 2007; 1: 88 [PMID: 17877816 DOI: 10.1186/1752-1947-1-88]
73. Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol 2008; 27: 1063-1066 [PMID: 18563514 DOI: 10.1007/s10067-008-0885-1]
74. Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A. Development of autoimmune hepatitis in a child with systemiconset juvenile idiopathic arthritis during therapy with etanercept. J Clin Rheumatol 2008; 14: 297-298 [PMID: 18824922 DOI: 10.1097/RHU.0b013e318188b1df]
75. Cueto R, Valdivieso P, Lucena MI, Garcia-Arias C, Andrade RJ, Gonzalez-Santos P. Statins: hepatic disease and hepatotoxicity risk. Open Gastroenterol J 2008; 2: 18-23 [DOI: 10.2174 /1874259900802010018]
76. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-591 [PMID: 15162892 DOI: 10.1592/phco.24.6.584.34738]
77. Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs 2010; 24 Suppl 1: 25-27 [PMID: 21175232 DOI: 10.2165/11586210-0000 00000-00000]
78. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001-1003 [PMID: 19370307 DOI: 10.1007/s10067-009-1179-y]
79. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003; 14: 229-232 [PMID: 14660270 DOI: 10.1080/09546 630310020470]
80. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005; 16: 347-349 [PMID: 16428159 DOI: 10.1080/09546630500424722]
81. Kleiner DE, Berman D. Pathologic changes in ipilimumabrelated hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-2240 [PMID: 22434096 DOI: 10.1007/ s10620-012-2140-5]
82. Efe C. Drug induced autoimmune hepatitis and TNF-a blocking agents: is there a real relationship? Autoimmun Rev 2013; 12: 337-339 [PMID: 22841985 DOI: 10.1016/ j.autrev.2012.03.010]
83. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. Liver injury from tumor necrosis factor-a antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-564.e3 [PMID: 23333219 DOI: 10.1016/j.cgh.2012.12.025]